Document is current
Any future updates will be listed below
-
Authors
Sivakumar, Shivan https://orcid.org/0000-0002-5175-2697
Jainarayanan, Ashwin
Arbe-Barnes, Edward
Sharma, Piyush Kumar
Leathlobhair, Maire Ni
Amin, Sakina https://orcid.org/0000-0002-5680-8928
Reiss, David J. https://orcid.org/0000-0001-5392-3034
Heij, Lara https://orcid.org/0000-0002-0602-3356
Hegde, Samarth
Magen, Assaf https://orcid.org/0000-0001-5473-274X
Tucci, Felicia https://orcid.org/0000-0001-5813-9708
Sun, Bo https://orcid.org/0000-0002-5507-6657
Wu, Shihong
Anand, Nithishwer Mouroug https://orcid.org/0000-0003-0852-7141
Slawinski, Hubert https://orcid.org/0000-0002-8996-8477
Revale, Santiago https://orcid.org/0000-0001-5219-9582
Nassiri, Isar https://orcid.org/0000-0003-1886-1151
Webber, Jonathon
Hoeltzel, Gerard D.
Frampton, Adam E. https://orcid.org/0000-0002-1392-2755
Wiltberger, Georg
Neumann, Ulf
Charlton, Philip https://orcid.org/0000-0003-0752-1960
Spiers, Laura
Elliott, Tim https://orcid.org/0000-0003-1097-0222
Wang, Maria
Couto, Suzana
Lila, Thomas
Sivakumar, Pallavur V.
Ratushny, Alexander V.
Middleton, Mark R. https://orcid.org/0000-0003-0167-1685
Peppa, Dimitra
Fairfax, Benjamin https://orcid.org/0000-0001-7413-5002
Merad, Miriam https://orcid.org/0000-0002-4481-7827
Dustin, Michael L. https://orcid.org/0000-0003-4983-6389
Abu-Shah, Enas https://orcid.org/0000-0001-5033-8171
Bashford-Rogers, Rachael https://orcid.org/0000-0002-6838-0711
- License Information
-
More Information
Article History
Received: 28 September 2023
Accepted: 11 December 2024
First Online: 6 February 2025
Competing interests
: S.S. held a personal fellowship from BMS during this study with a grant provided to conduct experiments and also has research funding from Alchemab, has received speaker fees and travel grants from Astrazeneca, Novartis and Servier; and also conducts trials with Astrazeneca, Novartis, Roche, Genentech and BioNTech. E.A.B. is a contributor to intellectual property licensed by Oxford University Innovation to AstraZeneca and held a research award from Guts UK/Dr Falk during this project. D.J.R., M.W., S.C., T.L., P.V.S., and A.V.R. are current or former employees and shareholders of BMS. M.R.M. reports grants from GRAIL, Roche, Astrazeneca, BMS, Infinitopes, Immunocore, and study fees from BMS, Pfizer, MSD, Regeneron, BiolineRx, Replimune and Novartis outside of the submitted work. M.L.D. is on the SAB for Adaptimmune and Singula Bio, consults for Molecular Partners, Enara Bio, Labgenius and Astra Zeneca, and undertakes research supported by BMS, Cue Biopharma, Boehringer Ingelheim, Regeneron and Evolveimmune outside the submitted work. The remaining authors declare no competing interests. R.B.-R. is a co-founder of Alchemab Therapeutics Ltd and consultant for Alchemab Therapeutics Ltd, Roche, Enara Bio, UCB and GSK.
